| Literature DB >> 27766027 |
Karolina Niska1, Narcyz Knap1, Anna Kędzia2, Maciej Jaskiewicz3, Wojciech Kamysz3, Iwona Inkielewicz-Stepniak1.
Abstract
Objectives: In dentistry, silver nanoparticles (AgNPs) have drawn particular attention because of their wide antimicrobial activity spectrum. However, controversial information on AgNPs toxicity limited their use in oral infections. Therefore, the aim of the present study was to evaluate the antibacterial activities against a panel of oral pathogenic bacteria and bacterial biofilms together with potential cytotoxic effects on human gingival fibroblasts of 10 nm AgNPs: non-functionalized - uncapped (AgNPs-UC) as well as surface-functionalized with capping agent: lipoic acid (AgNPs-LA), polyethylene glycol (AgNPs-PEG) or tannic acid (AgNPs-TA) using silver nitrate (AgNO3) as control.Entities:
Keywords: antibacterial activity; antibiofilm activity; capping agent; cytotoxicity; human gingival fibroblasts; silver nanoparticles
Mesh:
Substances:
Year: 2016 PMID: 27766027 PMCID: PMC5069413 DOI: 10.7150/ijms.16011
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
AgNPs characterization.
| Characterization | AgNPs-LA | AgNPs-PEG | AgNPs-TA | AgNPs-UC* |
|---|---|---|---|---|
| 9.5 ± 1.9 nm | 9.8 ± 2.0 nm | 10.0 ± 1.8 nm | 11.2± 2.1 nm | |
| 19.9 % | 20.0 % | 18.4 % | 19.6 % | |
| 55.96 m2/g | 53.5 m2/g | 53.4 m2/g | 54.8 m2/g | |
| 0.99 mg/mL | 1.10 mg/mL | 0.91 mg/mL | 50 mg/mL≠ | |
| 2.1E+14 particles/mL | 2.1E+14 particles/mL | 1.7E+14 particles/mL | NA | |
| 22.1 nm | 30.3 nm | 16.1 nm | 18.6 nm* | |
| -28.6 mV | -10 ± 10 mV | -34.9 mV | -33.9 mV* | |
| Lipoic Acid | mPEG 5 kDa | Tannic Acid | --- |
Supplied by manufacturer; *Note: evaluated by TEM, Zetasizer; concentration.
Figure 1Characterization of AgNPs using transmission electron microscopy (TEM). The representative microscopy images show shape of AgNPs; the histograms illustrate the range of particle size distribution obtained from TEM measurements of more than 300 particles: (A) AgNPs capped with lipoic acid, (B) AgNPs capped with polyethylene glycol, (C) AgNPs capped with tannic acid and (D) uncapped AgNPs.
Figure 2AgNPs-induced decrease in cell viability. The 24 h treatments of cells with AgNPs decreased HGF1 cell viability. Data are mean ± SD of 3-4 separate determinations. ***p < 0.001 as compared with control.
Susceptibility of Gram-negative anaerobic bacteria to AgNPs and AgNO3
Susceptibility of Gram-positive anaerobic bacteria to AgNPs and AgNO3.
Susceptibility of Staphylococcus strains and Streptococcus mutans to AgNPs.
| Minimal inhibitory concentration ( MIC ) in µg/mL | |||||
|---|---|---|---|---|---|
| Nanoparticles | S. aureus | S. aureus | S. aureus | S. epidermidis | S. mutans |
| AgNPs-LA | 5.0 | 2.5 | 5.0 | 5.0 | 5.0 |
| AgNPs-PEG | 2.5 | 5.0 | 10.0 | 0.625 | 10 |
| AgNPs-TA | 5.0 | 5.0 | 10.0 | 1.25 | 10 |
| AgNPs-UC | 2.5 | 2.5 | 10.0 | 0.3125 | 10 |
Figure 3Susceptibility of 1-day biofilm (MBEC) formed by reference strains bacteria to AgNPs (µg/mL)